| Synonyms: | |
| Status: | Phase 2 |
| Entry Type: | Small molecule |
| Molecule Category: | UNKNOWN |
| UNII: | 08WG8S0L8D |
Physicochemical Descriptors
| Property Name | Value |
|---|---|
| Molecular Formula | C23H22FN7O3 |
| Molecular Weight | 463.47 |
| AlogP | 2.61 |
| Hydrogen Bond Acceptor | 10.0 |
| Hydrogen Bond Donor | 0.0 |
| Number of Rotational Bond | 7.0 |
| Polar Surface Area | 101.36 |
| Molecular species | None |
| Aromatic Rings | 5.0 |
| Heavy Atoms | 34.0 |
Pharmacology
| Action | Mechanism of Action | Reference |
|---|---|---|
| INHIBITOR | Hepatocyte growth factor receptor inhibitor |
| Targets | EC50(nM) | IC50(nM) | Kd(nM) | Ki(nM) | Inhibition(%) | |
|---|---|---|---|---|---|---|
|
Enzyme
Kinase
Protein Kinase
TK protein kinase group
Tyrosine protein kinase Met family
|
- | 1-5 | - | - | - | |
|
Enzyme
Transferase
|
- | - | - | - | ||
|
Epigenetic regulator
Eraser
Histone deacetylase
HDAC class IIb
|
- | - | - | - | -8.21--3.49 |
Indications
| Mesh Heading | Maximum Phase | Mesh ID | Reference |
|---|---|---|---|
| Stomach Neoplasms | 2 | D013274 | ClinicalTrials |
| Neoplasms | 2 | D009369 | ClinicalTrials |
| Sarcoma, Clear Cell | 2 | D018227 | ClinicalTrials |
| Neoplasms | 2 | D009369 | ClinicalTrials |
| Stomach Neoplasms | 2 | D013274 | ClinicalTrials |
| Adenocarcinoma | 1 | D000230 | ClinicalTrials |
| Esophageal Neoplasms | 1 | D004938 | ClinicalTrials |
Cross References
| Resources | Reference |
|---|---|
| ChEMBL | CHEMBL3545212 |
| FDA SRS | 08WG8S0L8D |
| PubChem | 44181686 |
CONTENTS